News Briefs: Vertebral Augmentation Alternative; ReCor Recommits To Renal Denerv
This article was originally published in The Gray Sheet
Benvenue cleared for vertebral augmentation alternative. ReCor recommits to renal denervation. Spine surgery firm plans IPO. More news.
You may also be interested in...
A big slice of the device industry, from large-cap firms to venture capitalists, is trying to understand the new reality in the wake of Medtronic’s announcement that its Symplicity hypertension trial missed its endpoint
At the recent CIRCE meeting, researchers presented positive clinical data comparing Benvenue Medical Inc.’s Kiva vertebral compression fracture system versus Medtronic’s market-leading Kyphon kyphoplasty system, providing a boost for Benvenue, which is awaiting FDA 510(k) clearance of its device.
MAKO plans to acquire Pipeline Biomedical Holdings before it becomes part of Stryker. KCI, LifeCell and Systagenix to merge. Medicare announces rates for DME competitive bidding recompete. More news.